Heat Biologics Inc.

2.38+0.0100+0.42%Vol 43.57K1Y Perf -65.50%
May 2nd, 2022 16:00 DELAYED
BID2.38 ASK2.40
Open2.41 Previous Close2.37
Pre-Market- After-Market-
 - -  - -%
Target Price
16.40 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
★★★★+ —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     59.15
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.53 
Earnings Rating
Strong Sell
Market Cap61.04M 
Earnings Date
4th May 2022
Alpha-0.02 Standard Deviation0.32
Beta0.31 

Today's Price Range

2.332.48

52W Range

2.0710.85

5 Year PE Ratio Range

-1.70-1.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-
1 Month
-23.96%
3 Months
-10.53%
6 Months
-46.64%
1 Year
-65.50%
3 Years
181.96%
5 Years
-65.00%
10 Years
-

TickerPriceChg.Chg.%
HTBX2.380.01000.42
AAPL149.243.70002.54
GOOG2 334.0338.18001.66
MSFT266.825.32002.03
XOM92.111.16001.28
WFC43.711.50003.55
JNJ178.820.74000.42
FB202.622.58001.29
GE76.401.77002.37
JPM122.183.92003.31
Financial StrengthValueIndustryS&P 500US Markets
20.40
21.00
0.01
0.02
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-1 587.30
-1 558.50
-995.70
-
RevenueValueIndustryS&P 500US Markets
1.57M
0.06
-21.08
34.34
Earnings HistoryEstimateReportedSurprise %
Q04 2021-0.31-0.54-74.19
Q03 2021-0.29-0.30-3.45
Q02 2021-0.28-0.267.14
Q01 2021-0.29-0.31-6.90
Q03 2020-0.28-0.42-50.00
Q02 2020-0.56-0.3537.50
Q01 2020--0.77-
Q03 2019-1.12-1.120.00
Earnings Per EndEstimateRevision %Trend
3/2022 QR-0.46-27.78Negative
6/2022 QR-0.42-31.25Negative
12/2022 FY-1.55-20.16Negative
12/2023 FY-1.22-2.52Negative
Next Report Date-
Estimated EPS Next Report-0.46
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume43.57K
Shares Outstanding25.65K
Shares Float24.32M
Trades Count379
Dollar Volume104.61K
Avg. Volume132.88K
Avg. Weekly Volume76.70K
Avg. Monthly Volume167.59K
Avg. Quarterly Volume154.34K

Heat Biologics Inc. (NASDAQ: HTBX) stock closed at 2.38 per share at the end of the most recent trading day (a 0.42% change compared to the prior day closing price) with a volume of 43.57K shares and market capitalization of 61.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Heat Biologics Inc. CEO is Jeffrey Wolf.

The one-year performance of Heat Biologics Inc. stock is -65.5%, while year-to-date (YTD) performance is -21.71%. HTBX stock has a five-year performance of -65%. Its 52-week range is between 2.07 and 10.85, which gives HTBX stock a 52-week price range ratio of 3.53%

Heat Biologics Inc. currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 0.54, a price-to-sale (PS) ratio of 38.78, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -29.65%, a ROC of -30.78% and a ROE of -31.69%. The company’s profit margin is -%, its EBITDA margin is -1 558.50%, and its revenue ttm is $1.57 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from Heat Biologics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Heat Biologics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Heat Biologics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Heat Biologics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Heat Biologics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Heat Biologics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.33, ATR14 : 0.21, CCI20 : -91.49, Chaikin Money Flow : -0.36, MACD : -0.13, Money Flow Index : 45.56, ROC : -13.77, RSI : 40.40, STOCH (14,3) : 13.79, STOCH RSI : 1.00, UO : 29.07, Williams %R : -86.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Heat Biologics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary Rating-
0.00
-
0.00
-
0.00

Heat Biologics Inc.

Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells that secrete tumor-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.

CEO: Jeffrey Wolf

Telephone: +1 919 240-7133

Address: 627 Davis Drive, Morrisville 27560, NC, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

46%54%

News

Stocktwits